Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00777946 |
Recruitment Status :
Completed
First Posted : October 22, 2008
Results First Posted : June 15, 2011
Last Update Posted : July 12, 2011
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypertension | Drug: Aliskiren 300 mg Drug: Aliskiren/Amlodipine 300/5 mg Drug: Aliskiren/Amlodipine 300/10 mg Drug: Placebo to Aliskiren Drug: Placebo to Aliskiren/Amlodipine | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 818 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Eight-week Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (300/5 mg and 300/10 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension Not Adequately Responsive to Aliskiren 300 mg Monotherapy |
Study Start Date : | October 2008 |
Actual Primary Completion Date : | May 2009 |
Actual Study Completion Date : | May 2009 |

Arm | Intervention/treatment |
---|---|
Experimental: Aliskiren 300 mg/Amlodipine 5 mg
Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks.
|
Drug: Aliskiren/Amlodipine 300/5 mg
Aliskiren/Amlodipine 300/5 mg tablet taken orally once a day with a glass of water. Drug: Placebo to Aliskiren Placebo to Aliskiren tablet taken orally once a day. |
Experimental: Aliskiren 300 mg/Amlodipine 10 mg
Participants received 1 Aliskiren/Amlodipine 300/10 mg tablet + 1 Placebo to Aliskiren tablet orally once daily in the morning for 8 weeks.
|
Drug: Aliskiren/Amlodipine 300/10 mg
Aliskiren/Amlodipine 300/10 mg taken orally once a day with a glass of water. Drug: Placebo to Aliskiren Placebo to Aliskiren tablet taken orally once a day. |
Active Comparator: Aliskiren 300 mg
Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks.
|
Drug: Aliskiren 300 mg
Aliskiren 300 mg tablet taken orally once a day with a glass of water. Drug: Placebo to Aliskiren/Amlodipine Placebo to Aliskiren/Amlodipine taken orally once a day. |
- Change From Baseline to End of Study in the Mean Sitting Diastolic Blood Pressure (msDBP) [ Time Frame: Baseline, End of Study (Week 8) ]After the patient had been sitting for 5 minutes, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. The difference of the msDBP at baseline from the msDBP at 8 weeks was calculated using an Analysis of Covariance (ANCOVA) model with baseline as a covariate and treatment and region as two factors.
- Change From Baseline to End of Study in the Mean Sitting Systolic Blood Pressure (msSBP) [ Time Frame: Baseline, End of Study (Week 8) ]After the patient had been sitting for 5 minutes, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. The difference of the msSBP at baseline from the msSBP at 8 weeks was calculated using an ANCOVA model with baseline as a covariate and treatment and region as two factors.
- Number of Participants With Serious Adverse Events and Adverse Events [ Time Frame: 8 weeks ]
The number of participants with any Serious Adverse Event and the number of participants with Adverse Events in any system organ class.
Additional information about Adverse Events can be found in the Adverse Event Section.
- Percentage of Participants Achieving Blood Pressure Control [ Time Frame: 8 weeks ]
After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit.
Blood Pressure control was defined as having a mean sitting Diastolic Blood Pressure <90 and a mean sitting Systolic Blood Pressure <140.
- Percentage of Participants Achieving a Diastolic Blood Pressure Response [ Time Frame: 8 weeks ]
After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit.
A Diastolic Blood Pressure Response was defined as a mean sitting Diastolic Blood Pressure (msDBP) <90 mmHg or a ≥ 10 mmHg reduction in msDBP from baseline.
- Percentage of Participants Achieving a Systolic Blood Pressure Response [ Time Frame: 8 weeks ]
After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit.
A Systolic Blood Pressure Response was defined as a mean sitting Systolic Blood Pressure (msSBP) <140 mmHg or a ≥ 20 mmHg reduction in msSBP from baseline.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to Visit 1 must have a mean sitting Diastolic Blood Pressure (msDBP) ≥ 95 mmHg and < 110 mmHg at Visits 1 and 2
- Patients who have been treated for hypertension within the 4 weeks prior to - Visit 1 must have a msDBP ≥ 90 mmHg and < 110 mmHg at Visit 2
- All patients must have a msDBP ≥ 90 mmHg and < 110 mmHg at Visit 4
Exclusion Criteria:
- Severe hypertension
- Pregnant or nursing (lactating) women
- Women of child-bearing potential
- Previous or current diagnosis of heart failure New York Heart Association (NYHA Class II-IV)
- Serum potassium ≥ 5.3 mEq/L (mmol/L) at Visit 1
- Uncontrolled Type 1 or Type 2 diabetes mellitus
- Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with Similar chemical structures
- History of hypertensive encephalopathy or cerebrovascular accident, or history of transient ischemic attack (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention
Other protocol-defined inclusion/exclusion criteria may apply.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00777946
Estonia | |
Investigative site | |
Estonia, Estonia | |
France | |
Investigative site | |
France, France | |
Iceland | |
Investigative Site | |
Iceland, Iceland | |
India | |
Investigative Site | |
India, India | |
Italy | |
Investigative site | |
Italy, Italy | |
Korea, Republic of | |
Investigative Site | |
Republic of Korea, Korea, Republic of | |
Lithuania | |
Investigative Site | |
Lithuania, Lithuania | |
Spain | |
Investigative Site | |
Spain, Spain | |
Venezuela | |
Investigative Site | |
Venezuela, Venezuela |
Study Chair: | Novartis | Novartis |
Responsible Party: | External Affairs, Novartis |
ClinicalTrials.gov Identifier: | NCT00777946 |
Other Study ID Numbers: |
CSPA100A2303 |
First Posted: | October 22, 2008 Key Record Dates |
Results First Posted: | June 15, 2011 |
Last Update Posted: | July 12, 2011 |
Last Verified: | June 2011 |
Aliskiren, Amlodipine, Non-responder to aliskiren |
Hypertension Vascular Diseases Cardiovascular Diseases Amlodipine Antihypertensive Agents Calcium Channel Blockers |
Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Calcium-Regulating Hormones and Agents Physiological Effects of Drugs Vasodilator Agents |